Biomea Fusion to Host Conference Call to Announce Topline Results From Phase II COVALENT-111 Study in Patients With Type 2 Diabetes (T2D)
Biomea Fusion to Host Conference Call to Announce Topline Results From Phase II COVALENT-111 Study in Patients With Type 2 Diabetes (T2D)
Tuesday, December 17, 2024 at 8:00 am EST
2024年12月17日，星期二，东部标准时间上午8:00
REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Tuesday, December 17, 2024 at 8:00 am EST to present topline results from COVALENT-111, the company's Phase II trial of icovamenib in patients with type 2 diabetes.
加利福尼亚州红木城，2024年12月16日（全球新闻社）-- Biomea Fusion, Inc.（"Biomea"）（纳斯达克：BMEA）是一家临床阶段的生物制药公司，致力于发现和开发口服共价小分子药物，以治疗和改善糖尿病、肥胖症以及遗传性癌症患者的生活。今天宣布将于2024年12月17日星期二上午8:00东部标准时间召开电话会议和网络广播，以呈现COVALENt-111的初步结果，这是该公司在2型糖尿病患者中进行的icovamenib II期临床试验。
Conference Call and Webcast Details
Webcast of Biomea's investor update on Tuesday, December 17, 2024, at 8:00 am EST will be available to registered attendees under the Investors and Media section of the company's website at . A replay of the presentation will be archived on Biomea's site following the event.
电话会议和网络直播细节
Biomea投资者更新的网络广播将于2024年12月17日（星期二）上午8:00（东部标准时间）在公司网站的投资者和媒体部分提供给注册的与会者， 演示的重播将在活动后存档在Biomea的网站上。
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.
关于Biomea Fusion
Biomea Fusion是一家处于临床阶段的生物制药公司，专注于发现和开发口服共价小分子，以改善糖尿病、肥胖症和遗传性癌症患者的生活。共价小分子是一个合成化合物，能永久性地与其目标蛋白形成结合，并且相比于传统的非共价药物，提供了许多潜在的优势，包括更高的靶向选择性、更低的药物暴露和能够驱动更深、更持久的反应。
We are utilizing our proprietary FUSION System to discover, design and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.
我们正在利用我们专有的FUSION系统来发现、设计和开发一系列下一代共价结合小分子药物，旨在最大化患者的临床获益。我们希望对我们服务的患者的疾病治疗产生重大影响。我们的目标是治愈。
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
请访问我们的官方网站 biomeafusion.com，并关注我们 LinkedIn, X 和 脸书.
Contact:
Ramses Erdtmann
COO & President of Biomea Fusion
re@biomeafusion.com
联系:
拉美西斯·埃尔德特曼
Biomea Fusion 的首席运营官兼总裁
re@biomeafusion.com
